Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines. by David Herrero Martín (286820)

“…D) Fenretinide did not decrease mRNA levels of FOXO1 in aRMS cells. qRT–PCR was carried out after treatment with an IC₅₀ concentration of fenretinide during different time points (24–48–72 hours). …”

Cytotoxicity (as of %Control) IC₅₀ value (mean ±SD in µM) of the tested compounds vs. Positive controls Cisplatin and doxorubicin against gastrointestinal and colorectal... by MohammedBashar Al-Qazzan (22439236)

Aquaporin 2 Mutations in <i>Trypanosoma brucei gambiense</i> Field Isolates Correlate with Decreased Susceptibility to Pentamidine and Melarsoprol by Fabrice E. Graf (469055)

“…Here we describe two different kinds of <i>TbAQP2</i> mutations found in <i>T. b. gambiense</i> field isolates: simple loss of <i>TbAQP2</i>, or loss of wild-type <i>TbAQP2</i> allele combined with the formation of a novel type of <i>TbAQP2/3</i> chimera. …”

Pre-treatment with CDDO-Me decreases IR-induced DNA damage in a variety of non-cancerous cells. by Mariam El-Ashmawy (678638)

“…Data analyzed and calculated using Open Comet software [tail moment = tail length x tail DNA percentage]. Mean ± SEM of >50 cells per condition, *p<0.05 using t-test (compared to 3 Gy DMSO). …”

AMPK activation increases FOXO3 protein expression. by Yasuo Ido (172159)

Decreased IFNγ production by Ly49H⁺ NK cells in A/J mice. by Nassima Fodil (669326)

Decreased remyelination initiation is observed in Scribble cKO mice following focal demyelination in corpus callosum. by Andrew A. Jarjour (343100)

“…<i>n</i> = 3 mice per genotype. * <i>p</i> < 0.05, ** <i>p</i> < 0.01, *** <i>p</i> < 0.001 versus Scrib WT CL. Scale bars: A,B,D,E: 2 μm. J,K: 50 μm.</p>…”

Living cells are decreased in the PDL on the pressure side of a Pn−/− molar tooth subjected to experimental tooth movement. by Hideyuki Tanabe (243557)

WNF decreases Aβ peptides generation in HEK293 and SH-SY5Y human cells. by Htut Htut Htoo (3686641)

Decreased CCL2 levels protect A20^AEC-KO mice against influenza A infection by Jonathan Maelfait (181048)

Clinical characteristics of patients in the increased-, stable-, and decreased-RPR groups. by Kazuhiko Ikeuchi (9234268)

Subjects:

P2X7 is functionally expressed in the ovarian carcinoma cell line SKOV-3. by José David Nuñez-Ríos (18823719)

Subjects:

Tempol and L-NAME help prevent the decrease in F_max. by Travis L. Dutka (321984)

Decrease in Vitamin D Status in the Greenlandic Adult Population from 1987–2010 by Nina O. Nielsen (490187)

“…In all age-groups it decreased from 1987 to 2005–2010 (32%–58%). Low 25(OH)D3 concentrations (<50 nmol/L) were present in 77% of the 18–29 year old and decreased with age. …”

Resveratrol induces senescence through activation of p53, p21^CIP1 and p16^INK4A. by Mehtap Kilic Eren (591048)

Terpenoids decrease single-channel activity of L-AChRs elicited by ACh. by Guillermina Hernando (553795)

Drugs which cluster on the 'anxiolytic' group decrease 5-HT turnover in the brain. by Caio Maximino (100467)

“…Points represent means and error bars represent standard errors. A negative correlation is found between the decrease in serotonin turnover and the increase in time on white produced by a drug (r² = 0.5688, p = 0.0073).…”

Decreased myofibroblasts in the peritumoral region and high expression of MMP-7 in Pan02 S.C. tumor of <i>S100a4-Cre; Ext1</i>^<i>f/f</i> mice. by Ayumi Niwa (6256790)

“…Decreased gene expression is indicated in blue, and increased gene expression is indicated in red (fold change > 2, moderate t-test, <i>P</i> < 0.05; N = 3 for each cohort). …”

The influence of H₂O₂ on <i>P</i>. <i>berghei</i> infection in <i>A</i>. <i>stephensi</i>. by Li Gao (131516)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”